Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

In epilepsy, brain-responsive stimulation passes long-term tests

Key clinical point: Brain-responsive stimulation reduced seizure frequency and could assist patient management.

Major finding: Seizure reduction was 84% after 3 years in the real-world analysis and 75% in the extension study.

Study details: Retrospective real-world analysis (n = 150) and prospective extension study (n = 230).

Disclosures: The extension study was funded by NeuroPace. NeuroPace supported data entry and institutional review board submission for the real-world trial. Some study investigators reported owning stock in, being an employee of, receiving support from, and/or consulting for NeuroPace.


Nair DR et al. Neurology. 2020 Jul 20. doi: 10.1212/WNL.0000000000010154.

Razavi B et al. Epilepsia. 2020 Jul 13. doi: 10.1111/epi.16593.